Guidance issued by NICE (England) for treating neuroendocrine tumours (NETs) Final guidance recommending everolimus (Infinitor, Novartis) and sunitinib (Sutent, Pfizer) to treat neuroendocrine tumours (NETs). The drugs are recommended as an option for pancreatic NETs that cannot be operated on and have progressed. Everolimus is also recommended as an option for those with NETs of…
uk: Two eye treatments for serious diabetic eye conditions
Two eye treatments for serious diabetic eye condition – final draft guidance NICE recommended aflibercept solution for injection (Eylea, Bayer Pharma), and dexamethasone intravitreal(i) implant (Ozurdex, Allergan) as possible treatment options for some people with diabetic macular oedema, in two separate pieces of final draft guidance published (2 June). This oedema is a common complication…
uk: Device avoids surgery for enlarged prostate
Plans to support device that avoids surgery for enlarged prostate glands. A new device to relieve urinary tract problems caused by enlarged prostate glands in men is the focus of NICE draft guidance that opens for consultation (Friday 29 May 2015). Views on its draft medical technology guidance – provisionally recommending the UroLift system for treating…